Tempest Therapeutics Inc (TPST) - News Archive

In a groundbreaking turn of events, Tempest Therapeutics, Inc. has just been awarded Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for its innovative treatment, amezalpat (TPST1120), aimed at comb...

Understanding the AnnouncementOn February 7, 2025, Tempest Therapeutics, Inc. (NASDAQ: TPST), a clinical-stage biotechnology company renowned for its innovative approaches to cancer treatment, made an important debut co...

Tempest Therapeutics Expands Workforce Incentives with Stock Option Grants under Nasdaq Listing Rule 5635(c)(4) In a significant move that reflects its ongoing commitment to fostering talent and promoting growth within...

: Tempest Therapeutics, a biopharmaceutical company focused on innovative cancer therapies, has announced a significant partnership with Roche to advance their Amezalpat combination therapy into a pivotal Phase 3 clinic...

Tempest Therapeutics Extends Its Stockholder Rights Plan: What It Means for InvestorsOn October 10, 2024, Tempest Therapeutics, Inc. (Nasdaq: TPST), a rising star in the biotechnology sector focusing on innovative cance...

In a recent announcement, Tempest Therapeutics, Inc. (Nasdaq: TPST), a company focused on advancing innovative cancer therapies, has made a significant move by granting nonqualified stock options to its employees. Effec...

In a recent press release, Tempest Therapeutics, a clinical-stage biotechnology company specializing in targeted and immune-mediated therapeutics to combat cancer, has revealed the granting of nonqualified stock options...

Expansion of leadership team to strengthen global clinical expertiseTempest Therapeutics Inc, a leading healthcare company, has recently appointed Troy M. Wagner as its new Vice President of Quality Assurance. This stra...

Tempest Therapeutics Announces Success in End-of-Phase 2 Meeting with FDA for Innovative Cancer Therapy BRISBANE, Calif., Aug. 15, 2024 In a significant development for cancer therapeutics, Tempest Therapeutics, Inc. (N...

Tempest Therapeutics, a clinical-stage oncology company, has unveiled new survival data for their groundbreaking therapeutic drug, amezalpat (TPST-1120). The data shows a significant improvement in median overall surviv...

Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for a significant proportion of cancer-related deaths worldwide. The limited effectiveness of existing treatment options and the high m...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company devoted to advancing first-in-class targeted and immune-mediated therapies to combat cancer, has made significant strides with two key an...

BRISBANE, Calif. - Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company specializing in the development of innovative cancer therapeutics, has recently made several significant announcements...

Tempest Therapeutics TPST-1120 Shows Promise in Reducing Kidney Cancer Growth as a Monotherapy and in Combination with Chemotherapy and Immunotherapy, According to Preclinical Data Presented at AACR Annual Meeting Tempe...

:This article discusses the recent publication of positive clinical data regarding TPST-1120, a novel targeted and immune-mediated therapeutic developed by Tempest Therapeutics, Inc. The Phase 1 trial evaluated TPST-112...

Tempest Therapeutics, Inc., a leading clinical-stage biotechnology company, recently presented new preclinical data at the Society for Immunotherapy of Cancer (SITC) 2024 Spring Scientific Meeting. The data showcased th...

Renal Cell Carcinoma (RCC) accounts for approximately 3% of all adult cancers and remains a significant health burden worldwide. With limited treatment options available, there is a pressing need for innovative therapeu...

Brisbane, Calif. - Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company known for its development of first-in-class therapeutics, recently made an exciting announcement that could have a signific...

Tempest Therapeutics, Inc., a leading clinical-stage oncology company, is further solidifying its commitment to advancing innovative cancer treatments. The company announced today that its Compensation Committee has gra...